Location History:
- München, DE (2015)
- Munich, DE (2015 - 2016)
Company Filing History:
2 out of 441 
1 out of 721 
Years Active: 2015-2016
Title: **Ulrike Schubert: Pioneering Antibody Research in Munich**
Introduction
Ulrike Schubert is a remarkable inventor based in Munich, Germany, known for her innovative contributions to the field of antibody research. With two patents to her name, she has made significant strides in developing therapeutic antibodies that target critical proteins associated with various disorders, including cancer.
Latest Patents
Ulrike Schubert's latest patents focus on groundbreaking advancements in antibody technology. The first patent is titled "Anti-MST1R antibodies and uses thereof." This invention provides recombinant antigen-binding regions and antibodies that are specific for MST1R, a protein integral to numerous disorders such as cancer. These antibodies have broad applications, including therapeutic treatments and diagnostic purposes, and enable further investigation into MST1R's role in tumor progression.
Her second patent features an antibody targeting the osteoclast-related protein Siglec-15. This isolated antibody effectively inhibits osteoclast formation and/or osteoclastic bone resorption, which is vital for addressing bone-related conditions. The detailed structure of this antibody includes specific sequences that enhance its binding affinity.
Career Highlights
Currently, Ulrike Schubert is employed by Daiichi Sankyo Company, Limited, where she continues to advance her research and development initiatives. Her work is highly regarded in the scientific community, and she is recognized for her expertise in antibody engineering and therapeutic applications.
Collaborations
Throughout her career, Schubert has collaborated with esteemed colleagues such as Toshiaki Ohtsuka and Toshinori Agatsuma. These professional relationships not only enhance her research but also contribute to the advancement of innovative solutions in the biopharmaceutical industry.
Conclusion
Ulrike Schubert stands out as a leading inventor in the field of antibody research. Her contributions through her patents reflect significant progress in understanding and treating complex diseases. As she continues her work at Daiichi Sankyo Company, Limited, her innovations promise to impact the future of medical treatments significantly.